IN THE CLAIMS

Please cancel claims 7, 12, 13, 22, 23, 54, 63, 67 and 68, and amend claims 1, 11, 14, 17, 19-21, 34, 41, 51, 58-60, 66 and 71 as follows:

B1

1. (CURRENTLY AMENDED) A pharmaceutical composition comprising:

agent i) selected from the group consisting of an insulin, an insulin analog that binds an insulin receptor and lowers blood glucose and that differs from a naturally occurring insulin by one or more amino acid differences, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog,

agent ii) selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and

agent iii) an insulin sensitizer; and

a pharmaceutically acceptable non-ionic surfactant, wherein the non-ionic surfactant is a block copolymer of propylene oxide and ethylene oxide;

wherein the insulin-related peptide is selected from the group consisting of C-peptide, glucagon-like peptide-1 (GLP-1), amylin, insulin-like growth factor-1 (IGF-1) and IGF-1 bound to binding protein 3.

2. (ORIGINAL) The composition of claim 1 wherein said agent i) is an insulin.

3. (ORIGINAL) The composition of claim 2 wherein said insulin is selected from the group consisting of human insulin, porcine insulin and bovine insulin.

4. (ORIGINAL) The composition of claim 1 wherein said agent i) is an insulin analog.

5. (ORIGINAL) The composition of claim 4 wherein said insulin analog is selected from the group consisting of Lys^{B28} insulin, Pro^{B29} insulin and Asp^{B28} insulin.

6. (ORIGINAL) The composition of claim 1 wherein said agent ii) is an insulin-related peptide.

7. (CANCELLED)

8. (ORIGINAL) The composition of claim 1 wherein said agent iii) is an insulin sensitizer of the glitazone family.

9. (ORIGINAL) The composition of claim 1 which is stabilized for administration by a medication infusion pump.

10. (PREVIOUSLY CANCELLED)

B2 11. (CURRENTLY AMENDED) The composition of claim 1, which is a liquid and comprises ~~comprising~~ about 1.5 to about 40 mg/ml of agent i) and about 1.5 to about 40 mg/ml of agent ii).

12. (CANCELLED)

13. (CANCELLED)

B3 14. (CURRENTLY AMENDED) The composition of claim ~~13~~ 11 comprising ~~about 1.5 to about 40 mg/ml of agent i), about 1.5 to about 40 mg/ml of agent ii) and~~ an amount of said non-ionic surfactant affording a concentration less than the critical micellar concentration of said composition.

15. (PREVIOUSLY CANCELLED)

16. (PREVIOUSLY CANCELLED)

B4 17. (CURRENTLY AMENDED) The composition of claim 1, which is a liquid and comprises ~~comprising~~ about 0.5 to about 40 mg/ml of agent i) and about 0.05 to about 12 mg/ml of agent iii).

18. (PREVIOUSLY CANCELLED)

19. (CURRENTLY AMENDED) The composition of claim 1, which is a liquid and comprises ~~comprising~~ about 0.05 to about 12.5 mg/ml of agent ii) and about 0.05 to about 12.5 mg/ml of agent iii).

B5

20. (CURRENTLY AMENDED) The composition of claim 1 further comprising ~~two~~ one or more additional compounds of agent i), ~~two or more compounds~~ of agent ii), or ~~two or more compounds~~ of agent iii).

21. (CURRENTLY AMENDED) A pharmaceutical composition comprising

i) at least one agent selected from the group consisting of an insulin, an insulin analog, a physiologically active insulin fragment and a physiologically active insulin analog fragment and

ii) at least one agent selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulated-related peptide analog fragment, and

iii) an insulin sensitizer; and

iv) optionally, a pharmaceutically acceptable carrier;

wherein said agent ii) comprises a hydrophobic portion that is coated with a pharmaceutically acceptable non-ionic surfactant that is a block copolymer of propylene oxide and ethylene oxide.

22. (CANCELLED)

23. (CANCELLED)

24. (PREVIOUSLY CANCELLED)

25. (ORIGINAL) The composition of claim 21 which is stabilized for administration by a medication infusion pump.

26. (ORIGINAL) A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 1.

27. (ORIGINAL) The method of claim 26 wherein said composition is administered to said patient by a medication infusion pump.

28. (ORIGINAL) The method of claim 27 wherein said medication infusion pump is reusable.

29. (ORIGINAL) The method of claim 27 wherein said medication infusion pump is non-reusable.

30. (ORIGINAL) The method of claim 27 wherein said medication infusion pump is implantable.

31. (ORIGINAL) The method of claim 27 wherein said medication infusion pump is externally mountable.

32. (ORIGINAL) The method of claim 26 wherein said composition is administered continually.

33. (PREVIOUSLY AMENDED) A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 1 .

B6

34. (CURRENTLY AMENDED) A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim ~~12~~ 11.

35. (PREVIOUSLY AMENDED) A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 14.

36. (PREVIOUSLY AMENDED) A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 17.

37. (PREVIOUSLY AMENDED) A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 19.

38. (ORIGINAL) The method of claim 37 wherein said diabetes is type 2 diabetes.

39. (ORIGINAL) A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 20.

40. (ORIGINAL) A method of treating diabetes comprising the step of administering to a patient in need of such treatment the pharmaceutical composition of claim 21.

B1

41. (CURRENTLY AMENDED) A method of treating diabetes comprising the step of administering to a patient in need of such treatment pharmaceutical compositions a)-c), wherein

composition a) comprises

i) at least one agent selected from the group consisting of an insulin, an insulin analog that binds an insulin receptor and lowers blood glucose and that differs from a naturally occurring insulin by one or more amino acid differences, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog, and

ii) a pharmaceutically acceptable carrier,

composition b) comprises

i) at least one agent selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, and

ii) a pharmaceutically acceptable carrier, and

composition c) comprises

i) an insulin sensitizer, and

ii) a pharmaceutically acceptable carrier;

B7 conclude

wherein the insulin-related peptide is selected from the group consisting of C-peptide, glucagon-like peptide-1 (GLP-1), amylin, insulin-like growth factor-1 (IGF-1) and IGF-1 bound to binding protein 3.

42. (ORIGINAL) The method of claim 41 wherein each of said compositions is administered to said patient using a separate delivery device.

43. (ORIGINAL) The method of claim 42 wherein each said delivery device is a medication infusion pump.

44. (ORIGINAL) The method of claim 41 wherein each of said compositions is administered at a different rate.

45. (ORIGINAL) The method of claim 41 wherein each of said compositions is administered continually.

46. (PREVIOUSLY AMENDED) The method of claim 41 wherein compositions a) and b) are administered to said patient using a single delivery device.

47. (ORIGINAL) The method of claim 46 wherein said composition b) further comprises at least one pharmaceutically acceptable non-ionic surfactant.

48. (PREVIOUSLY AMENDED) The method of claim 41 wherein compositions a) and c) are administered to said patient using a single delivery device.

49. (PREVIOUSLY AMENDED) The method of claim 41 wherein compositions b) and c) are administered to said patient using a single delivery device.

50. (PREVIOUSLY AMENDED) The method of claim 41 wherein compositions a), b) and c) are administered to said patient using a single delivery device.

51. (CURRENTLY AMENDED) A method of making a pharmaceutical composition useful in treating diabetes, said method comprising the step of combining agents i) - iii), wherein

agent i) is selected from the group consisting of an insulin, an insulin analog that binds an insulin receptor and lowers blood glucose and that differs from a naturally occurring insulin by one or more amino acid differences, a physiologically active fragment of said insulin and a physiologically active fragment of said insulin analog,

agent ii) is selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment;

wherein agents i) and ii) are combined with a pharmaceutically acceptable non-ionic surfactant that is a block copolymer of propylene oxide and ethylene oxide, and

agent iii) is an insulin sensitizer;

wherein the insulin-related peptide is selected from the group consisting of C-peptide, glucagon-like peptide-1 (GLP-1), amylin, insulin-like growth factor-1 (IGF-1) and IGF-1 bound to binding protein 3.

52. (ORIGINAL) The method of claim 51 wherein said agents are combined with a pharmaceutically acceptable carrier.

53. (PREVIOUSLY CANCELLED)

54. (CANCELLED)

55. (PREVIOUSLY CANCELLED)

56. (PREVIOUSLY CANCELLED)

57. (PREVIOUSLY CANCELLED)

58. (CURRENTLY AMENDED) A method of treating diabetes and at least one side effect thereof which comprises the step of administering to a patient in need of such treatment a pharmaceutical composition comprising

a) at least one agent selected from the group consisting of an insulin, an insulin analog that binds an insulin receptor and lowers blood glucose and that differs from a naturally occurring insulin by one or more amino acid differences, a physiologically active insulin fragment and a physiologically active insulin analog fragment,

b) at least one agent selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment and a physiologically active insulin-related peptide analog fragment, wherein said agent is effective in treating said side effect,

c) a pharmaceutically acceptable non-ionic surfactant that is a block copolymer of propylene oxide and ethylene oxide, and

d) an insulin sensitizer;

wherein the insulin-related peptide is selected from the group consisting of C-peptide, glucagon-like peptide-1 (GLP-1), amylin, insulin-like growth factor-1 (IGF-1) and IGF-1 bound to binding protein 3.

59. (CURRENTLY AMENDED) A pharmaceutical composition comprising agents i) - iii), wherein

agent i) is selected from the group consisting of an insulin mimetic material,

agent ii) is selected from the group consisting of an insulin-related peptide, an insulin-related peptide analog, a physiologically active insulin-related peptide fragment, and a physiolgically active insulin-related peptide analog fragment, and

agent iii) is an insulin sensitizer;

wherein the insulin-related peptide is selected from the group consisting of C-peptide, glucagon-like peptide-1 (GLP-1), amylin, insulin-like growth factor-1 (IGF-1) and IGF-1 bound to binding protein 3; and

wherein agents i) and ii) are combined with a pharmaceutically acceptable non-ionic surfactant that is a block copolymer of propylene oxide and ethylene oxide.

60. (CURRENTLY AMENDED) The composition of claim 59 wherein said agent i) is a small molecule insulin mimetic material.

61. (ORIGINAL) The composition of claim 60 wherein the small molecule insulin mimetic material is L-783,281.

62. (ORIGINAL) The composition of claim 59 wherein said agent ii) is an insulin-related peptide.

63. (CANCELLED)

64. (ORIGINAL) The composition of claim 59 wherein said agent iii) is an insulin sensitizer of the glitazone family.

65. (ORIGINAL) The composition of claim 59 which is stabilized for administration by a medication infusion pump.

66. (CURRENTLY AMENDED) The composition of claim 59, which is a liquid and comprises ~~comprising~~ about 1.5 to about 40 mg/ml of agent i), about 1.5 to about 40 mg/ml of agent ii), and about 0.05 to about 12.5 mg/ml of agent iii).

67. (CANCELLED)

68. (CANCELLED)

69. (PREVIOUSLY CANCELLED)

70. (PREVIOUSLY CANCELLED)

B12

71. (CURRENTLY AMENDED) The composition of claim 59 further comprising ~~two~~ one or more additional compounds of agent i), ~~two or more compounds~~ of agent ii), or ~~two or more compounds~~ of agent iii).